Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Needs To Weigh Foreign Inspections More Heavily - SOCMA

This article was originally published in The Tan Sheet

Executive Summary

Despite plans to increase overseas inspections for fiscal 2010, FDA's refusal to risk-rank domestic and foreign manufacturers together puts U.S. firms at a disadvantage, according to the Society of Chemical Manufacturers and Affiliates

You may also be interested in...



FDA Foreign Inspections To Double In 2010, Led By Human Drugs And Food

FDA will shoot to double its inspections of foreign facilities in fiscal 2010 to more than 2,000

FDA Seeks Public Input On Secrets Of Profit-Motivated Adulteration

FDA plans to hold a public workshop this spring to begin the task of combating profit-motivated adulteration of regulated products

Import Contamination Risk Looms Larger For OTCs, Ex-Regulators Say

Over-the-counter drugs made with imported ingredients are at greater risk of contamination than prescription products, experts told a House panel on Nov. 1

Related Content

Topics

UsernamePublicRestriction

Register

PS103476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel